Food and Drug Administration
Dermatologic and Ophthalmic Drugs Advisory Committee
May 23, 2002
BLA 125036, AMEVIVEŽ, alefacept - indicated for the treatment of patients with chronic plaque psoriasis who are candidates for phototherapy or systemic therapy
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Biogen, Inc. - Briefing Document pdf doc
FDA - Briefing Document pdf doc
Errata pdf doc htm